These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19785071)

  • 41. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo.
    Rognoni E; Widmaier M; Haczek C; Mantwill K; Holzmüller R; Gansbacher B; Kolk A; Schuster T; Schmid RM; Saur D; Kaszubiak A; Lage H; Holm PS
    Cancer Gene Ther; 2009 Oct; 16(10):753-63. PubMed ID: 19363467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutics with replication--selective virus (RSV) for pancreatic cancer].
    Motoi F; Ottomo S; Ohmura N; Abe H; Egawa S; Sunamura M
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():223-7. PubMed ID: 16457255
    [No Abstract]   [Full Text] [Related]  

  • 43. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
    Mao CY; Hua HJ; Chen P; Yu DC; Cao J; Teng LS
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):282-7. PubMed ID: 19502169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells.
    Onimaru M; Ohuchida K; Egami T; Mizumoto K; Nagai E; Cui L; Toma H; Matsumoto K; Hashizume M; Tanaka M
    Cancer Gene Ther; 2010 Aug; 17(8):541-9. PubMed ID: 20395979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
    Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
    Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines.
    Eisold S; Linnebacher M; Ryschich E; Antolovic D; Hinz U; Klar E; Schmidt J
    World J Gastroenterol; 2004 Dec; 10(24):3583-9. PubMed ID: 15534911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity.
    Sauthoff H; Pipiya T; Heitner S; Chen S; Bleck B; Reibman J; Chang W; Norman RG; Rom WN; Hay JG
    Mol Ther; 2004 Oct; 10(4):749-57. PubMed ID: 15451459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
    He XP; Su CQ; Wang XH; Pan X; Tu ZX; Gong YF; Gao J; Liao Z; Jin J; Wu HY; Man XH; Li ZS
    Cancer Lett; 2009 Nov; 285(1):89-98. PubMed ID: 19481338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
    Ridwelski K; Fahlke J; Kuhn R; Hribaschek A; Kettner E; Greiner C; Florschuetz A; Manger T; Wilhelm G; Klein H; Hahnfeld S; Lippert H; Meyer F
    Eur J Surg Oncol; 2006 Apr; 32(3):297-302. PubMed ID: 16414235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.
    Dias JD; Guse K; Nokisalmi P; Eriksson M; Chen DT; Diaconu I; Tenhunen M; Liikanen I; Grénman R; Savontaus M; Pesonen S; Cerullo V; Hemminki A
    Eur J Cancer; 2010 Feb; 46(3):625-35. PubMed ID: 20006487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
    Büchler P; Reber HA; Eibl G; Roth MA; Büchler MW; Friess H; Isacoff WH; Hines OJ
    Int J Oncol; 2005 Oct; 27(4):1125-30. PubMed ID: 16142331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
    Kitabayashi H; Shimada H; Yamada S; Yasuda S; Kamata T; Ando K; Tsujii H; Ochiai T
    Oncol Rep; 2006 Apr; 15(4):913-8. PubMed ID: 16525679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents.
    Mantwill K; Köhler-Vargas N; Bernshausen A; Bieler A; Lage H; Kaszubiak A; Surowiak P; Dravits T; Treiber U; Hartung R; Gansbacher B; Holm PS
    Cancer Res; 2006 Jul; 66(14):7195-202. PubMed ID: 16849566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
    Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
    Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
    Akbulut H; Tang Y; Maynard J; Zhang L; Pizzorno G; Deisseroth A
    Clin Cancer Res; 2004 Nov; 10(22):7738-46. PubMed ID: 15570008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
    Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
    Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus.
    Sunamura M; Oonuma M; Motoi F; Abe H; Saitoh Y; Hoshida T; Ottomo S; Horii A; Matsuno S
    Hum Cell; 2002 Sep; 15(3):138-50. PubMed ID: 12703544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.